Angiogenesis inhibitor reduces edema to improve glioblastoma survivalAccording to a recently concluded study by researchers from the Massachusetts General Hospital, the positive effects of anti-angiogenesis drugs for treating the deadly brain tumor known as glioblastomas gives an impression of originating primarily from edema reduction and not from any direct anti-tumor effect.

The findings of this study suggest that antiangiogenesis therapy can enhance patient survival even in circumstances revolving cases of persistent tumor growth, according to Rakesh K. Jain, PhD, director of the Steele Laboratory in the MGH Department of Radiation Oncology, the study’s co-senior author.

This study is expected to offer a new paradigm to help physicians treating their patients with deadly brain tumors.